John M. Kane, MD

This episode, titled "Integrating Novel Mechanisms into Schizophrenia Treatment Practice," features panelist Mark Jankelow discussing the practical clinical considerations surrounding a novel muscarinic agent.

Explore 2024’s xanomeline–trospium: M1/M4 muscarinic therapy for schizophrenia, easing EPS and metabolic risks while raising GI concerns.

Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.

Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.

Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.

Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.

How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.

Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.

Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.

Experts share strategies to boost schizophrenia adherence—family partnership, early engagement, and newer antipsychotics to improve long‑term function.

How does John Kane, MD, address issues of cognition in schizophrenia?

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.

Compliance is a major issue in treatment of schizophrenia. How can compliance be improved, and can newer formulations make that compliance easier?